From bombs to bromides? Trump’s jousting with biopharma may well boil down to a handshake on drug prices
A few months ago, the prospect of an executive order from President Donald Trump on drug pricing would have been the cause of high anxiety in biopharma. After all, Trump settled into the White House loudly complaining of just how badly the drug industry has been ripping off the American public.
Now there are a variety of reports that an EO is coming — and the industry could be in for a mid-year boost if in fact Trump does as expected and keeps the directive limited in scope and impact.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.